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ABSTRACT 
Background/Objectives: Acute pancreatitis (AP) is one of the most common causes of hospitalization 
and severe cases are usually associated with a poor prognosis. Neutrophil to lymphocyte ratio (NLR) has 
been pointed as an indicator of systemic inflammation in several disorders. The aim of this study was to 
assess whether NLR at admission is able to predict severity of AP and some associated outcomes (need 
for ICU admission, in-hospital mortality, length of hospital stay > 7 days and organ failure development), 
while trying to establish the best cut-off value for outcomes. 
Materials and methods: This was a single-center retrospective study carried with clinical data from AP 
patients between January 2014 and December 2015. Four hundred and forty five patients were eligible for 
the study and NLR was calculated based on admission laboratory data. Patients were stratified according 
to severity, based on the Atlanta Classification, and comparative analysis was carried between groups.  
Results: A total of 391 patients presented with mild AP and 54 with moderate or severe AP. NLR for the 
severe group was significantly higher than for the mild group (13,9±13,6 versus 10,1±9,4, respectively). 
There were also statistical differences in NLRs between all groups of analyzed outcomes except for in-
hospital mortality. The best predictive NLR value for the stratification of AP severity was 9,2.  
Conclusions: This study shows a significant correlation between NLR at admission and the severity of 
AP. Higher NLR values also predicted the development of organ failure, ICU admission and longer 
hospitalizations. 
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INTRODUCTION 
Acute pancreatitis (AP) is an inflammatory disorder of the pancreas caused by an impairment in the 
secretion of pancreatic enzymes, usually due to an obstruction of the pancreatic ducts
1
. This leads to the 
accumulation of digestive enzymes in the acinar cells and interstitial space, which can be activated and 
cause acinar cell injury and a subsequent inflammation of the pancreatic parenchyma
2
. The most common 
cause of AP is widely recognized to be gallstones (almost half of all cases) followed by alcohol 
consumption, while other causes (such as hypertriglyceridemia, medications or iatrogenic) usually 
account for less than 10% of all episodes
3
. In about one third of all patients, a cause is not found
4
. 
AP still remains one of the most common causes of hospitalization due to gastrointestinal disease, with a 
reported increase in its incidence worldwide
3, 5
. In fact, global epidemiological studies have found 
incidence rates for AP ranging from 13 to 45 cases per 100000 persons every year in occidental 
countries
5
. Mild cases of AP (MAP, approximately 80% of all episodes
1
) are usually characterized by 
edema and inflammation restrict to the pancreas, with no other complications. These are usually self-
limited and carry very low morbidity and mortality rates
6, 7
. On the other hand, patients presenting with 
moderate or severe AP (SAP) can develop multiple complications, such as organ failure and/or pancreatic 
necrosis, with mortality rates as high as 30% in the most complicated groups
6, 8
. 
Therefore, a prompt identification of the severe cases should occur in order to prevent worst outcomes, 
which seem to be related to an uncontrolled systemic inflammatory response with multiorgan failure
8, 9
. 
For that reason, several scoring systems have been developed to help predict the severity of AP, including 
Ranson’s criteria, Glasgow score, APACHE-II score, BISAP and imaging scores (like Balthazar score 
and CTSI score)
2, 10
. However, these all have some major flaws that limit their use in the emergency 
department. For instance, both Ranson’s and Glasgow criteria need a 48h blood work-up (with some 
variables not routinely assessed) to be fully calculated, therefore missing the purpose of early identifying 
some severe cases; APACHE-II (Acute Physiology and Chronic Health Evaluation II) is a complex 
scoring system (not specific for acute pancreatitis) that requires more than 14 different variables; and 
BISAP (Bedside Index of Severity in Acute Pancreatitis), even though it is a simple score easily 
calculated in the emergency room, requires the realization of a chest x-ray. On the other hand, the 
imaging scoring systems (namely Balthazar and CT Severity Index) demand performing a CT at 
admission on all patients with suspected AP and did not exhibit better accuracy at predicting severe cases 
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of AP
11
. Furthermore, studies confirm that all described criteria have a relative low sensitivity in the early 
phases of the disease
10, 12, 13
, probably because they weight all the variables equally, not accounting for 
deleterious synergistic effects
13
. For all the listed reasons, new ways of quickly, easily and accurately 
evaluate the severity of new cases of AP are needed. 
The neutrophil-lymphocyte ratio (NLR) is an easily obtained parameter from routine white blood cell 
counts, which are performed in almost all emergency admissions. For that reason, this parameter has been 
presented over the last decade as a predictor of poor outcomes in several gastrointestinal disorders (such 
as acute appendicitis, acute cholecystitis and some malignant neoplasms, like hepatocellular, esophageal 
and colorectal carcinomas), often being considered a more reliable tool than the total white blood cell 
count for that purpose
14-18
. Regarding AP, some studies have shown a correlation between this ratio and 
the severity, mortality of AP, the length of hospitalization and need for ICU admission, demonstrating a 
prognostic value for the NLR with higher reliability than other common tools
19-21
. On the other hand, 
there have been some conflicting results too, and there are some concerns regarding the real usefulness of 
this marker in this context
22-24
. For instance, Gulen et al. proposed NLR was not effective at predicting 
AP mortality in the first 48 hours
22
. 
In this study, we aimed to assess whether NLR at admission correlates with AP severity and its adverse 
outcomes, namely need for ICU admission, longer length of stay (>7 days), presence of organ failure and 
in hospital mortality. We also studied the best NLR cut-off value to predict said outcomes.  
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METHODS 
Study design and patients 
We performed a retrospective cohort study including all patients with the diagnosis of AP between 1
st
 
January 2014 and 31
th
 December 2015 at Centro Hospitalar São João, a tertiary care center in Oporto, 
Portugal. During this period, from 504 patients presenting with AP, 59 were excluded from data analysis 
for the following reasons: pediatric age (n=10), HIV infection (n=1), lymphoproliferative disorders (n=4), 
immunosuppressive drugs (n=5), iatrogenic etiology (n=31) and missing clinical data (n=8). A total of 
445 patients was included. 
Data collection and definitions 
The study was approved by the Ethical Committee “Comissão de Ética para a Saúde do Centro Hospitalar 
São João”. The confidentiality and privacy of the data were guaranteed according to the Declaration of 
Helsinki. 
Data was obtained from electronic medical records and included demographic information (age, sex), 
laboratory data at admission, clinical data regarding the episode evolution (AP etiology, presence of pain, 
length of hospital stay, ICU admission, organ failure and in-hospital mortality) and radiologic findings 
(CT at admission or during hospitalization, if performed). 
AP diagnosis was confirmed for each patient if at least two of the following three criteria were present:  
(1) abdominal pain suggestive of AP; 
(2) serum amylase or lipase greater than three times the normal upper limit; 
(3) typical radiological findings. 
AP severity was defined based on the Revised Atlanta Classification
6
, meaning patients were considered 
to have mild AP if there were no complications or presence of organ failure, moderately severe acute 
pancreatitis if there was presence of transient organ failure (duration < 48h) and/or local or systemic 
complications, and severe acute pancreatitis if there was persistent organ failure (duration ≥ 48h). The 
modified Marshall scoring system
25
 was used to determine the presence of organ failure, with a score of 2 
or higher in each measurement indicating loss of organ function. For the purpose of statistical analysis, 
patients were grouped in two groups: MAP (mild acute pancreatitis, with no complications nor organ 
failure) and SAP (moderately severe and severe acute pancreatitis, with local or systemic complications 
and/or organ failure).  
NLR was calculated dividing the neutrophil count by the lymphocyte count for each patient at admission. 
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Statistical analysis 
Statistical analysis was performed using IBM SPSS Statistics 25, and a p value < 0,05 was accepted as 
statistically significant. Unless noted otherwise, categorical data was described using frequencies with 
proportions and continuous data using means with standard deviations. Comparison between groups was 
carried using the Fisher's exact or Chi-square tests for categorical data and Mann-Whitney U or Student’s 
t-test for continuous data, as appropriate. Correlation between NLR at admission and AP severity was 
determined based on Spearman’s Rank coefficient. ROC (receiver operating characteristic) curve analysis 
was performed for the studied outcomes with significant differences in NLR between groups in order to 
determine the best discriminating NLR cut-off value for each outcome. The optimal cut-off value for each 
ROC curve was computed based on the higher possible sensitivity and specificity values. Sensitivity, 
specificity, positive predictive value (PPV) and negative predictive value (NPV) were calculated for the 
results, and accuracy of prediction was estimated using the area under the curve (AUC) for each ROC 
curve. 
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RESULTS 
A total of 445 patients were included in the study, of which 391 presented with MAP (87,9%) and 54 
with SAP (12.1%). The most common etiology for AP cases was biliary lithiasic ductal obstruction 
(n=279, 62,7%), followed by alcohol abuse (n=73, 16,4%). In 72 cases (16,2%), no cause for AP was 
found either during the episode or the follow-up. Patient demographics and laboratory data at admission 
are presented in Table 1. Patients in the SAP group were significantly older, but no differences between 
groups were found regarding gender or etiology of pancreatitis. Need for ICU admission, prolonged 
hospital stay (> 7 days), organ failure and death were lower in the MAP group (Table 1). 
No differences were found in white blood cell counts (WBC) at presentation; on the other hand, the 
calculated mean NLR was significantly higher in MAP group (10,1±9,4 vs. 13,9±13,6 for SAP, 
p=0.003). The distribution of NLRs by severity of AP cases can be seen in Figure 1. 
Regarding the occurrence of adverse outcomes, we found a statistical difference between NLR in 
patients admitted to the ICU (16,6 vs 9,7 in the other group; p<0,001), in patients with a LOS > 7 days 
(12,5 vs 9,3 in the group with LOS < 7 days; p<0,001) and whenever organ failure was present (12,6 vs 
10,1 if no organ failure occurred; p=0,045). There were no statistical differences in NLR between 
groups according to in-hospital mortality (12,6 vs 10,4, if death occurred or not, respectively; p=0,099). 
A positive correlation between higher NLR values and severe cases was found using Spearman’s 
correlation test (r=0.130, p=0,003). A ROC curve for the prediction of AP severity using NLR was 
performed and the AUC for that curve was 0,623 (95% CI: 0,549-0,698); the NLR cut-off value 
determined for maximum accuracy was 9,2 (53,7% sensitivity, 65,5% specificity, 17,8% positive 
predictive value and 91,1% negative predictive value). ROC analysis for NLR and secondary outcomes 
also pointed 9,2 as the most accurate cut-off value at predicting organ failure and need for ICU 
admission; meanwhile, LOS>7 days was better predicted with a cut-off point of 7,9. AUC for all ROC 
curves and respective optimal cut-off points are presented in Table 2. Sensitivity, specificity and 
predictive values for the chosen cut-off (NLR = 9,2) at predicting the evaluated outcomes are presented 
in Table 3.  
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DISCUSSION 
Multiple studies have shown in the past the usefulness of NLR at predicting disease severity, recurrence 
and prognosis in several disorders
14-18
. In particular, the NLR has been studied before as a predictor of AP 
severity and unfavorable prognosis, being often proposed as an effective tool for that purpose
19-21
. 
Neutrophils have been shown to play a pivotal role in the propagation of the inflammation pathways in 
AP through cytokine and chemokine cascades, trypsin production
26
. Regarding lymphocyte counts, 
lymphocyte depletion was demonstrated in severe cases of AP, mainly because of premature apoptotic 
death of these cells (especially T CD8 subpopulations)
27
. For these reasons, it is expected that AP cases 
associated with necrosis or organ failure (i.e., SAP cases) develop higher levels of neutrophilia and 
lymphopenia, translating into higher NLR values
28
. As mentioned before, the most practical advantage of 
this parameter is the fact that it is readily obtained from a routine hemogram with leucocyte count in the 
emergency department, not needing further workups.  
In this study, we focused on assessing whether higher values of NLR calculated at admission correlate 
with worse outcomes. Our results show that SAP cases were generally associated with higher values of 
NLR than those of the MAP cases, therefore being an useful tool for stratification of AP severity. We also 
found NLR to be significantly higher in patients admitted to the ICU, with longer lengths of stay and with 
presence of organ failure (one of the most important factors at defining AP severity, as indicated by the 
Atlanta Classification of Acute Pancreatitis
6
).  
The biggest differences between studies regarding NLR in AP concern the optimal cut-off value for the 
severity stratification. Azab et al.
19
 and Jeon and Park
20 
suggested that the optimal NLR cut-off value at 
admission should be 5 or 4,76, respectively, while Suppiah et al.
21 
proposed it to be 10,6. We found 
higher sensitivity and specificity at predicting SAP cases with a cut-off point of 9,2 (62,3% accuracy, as 
determined by the AUC of the ROC curve), which is way closer to what Suppiah et al. found. We also 
could confirm the superiority of NLR over WBC count at distinguishing between MAP and SAP cases, as 
proposed by Azab et al., considering we found no statistical differences between WBC in both groups.  
Our study also showed that the NLR also has a decent accuracy at predicting the need for ICU admission 
(AUC 0,684), presence of organ failure (AUC 0,614) and length of stay > 7 days (AUC 0,605), but not at 
predicting in-hospital mortality (unlike previous studies), possibly because of the insufficient sample size. 
From the presented data, we can determine NLR at admission performs better at predicting need for ICU 
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admission comparing to the other examined outcomes, but its low positive predictive value possibly 
presents itself as an obstacle for that purpose, considering the high rate of false positives.  
Even though the accuracy of NLR at predicting AP severity may be lower than the reported accuracy of 
other currently used scoring systems
29
, the present study (and any other else, to our knowledge) directly 
compared these, and for that reason further research on the subject should be conducted. On the other 
hand, instead of considering the NLR an independent tool to predict AP severity, maybe it should be 
taken in account in association to other laboratory markers (and/or possibly already existing scoring 
systems) in order to improve its accuracy and diagnostic performance. Prospective research should be 
conducted for that matter. 
Some limitations can be evident in our study, mainly concerting the investigation design. As a 
retrospective study; a selection bias, inherent to this type of studies, is often present; and the outcomes 
assessment heavily depended on the medical records provided by others. A bigger sample size would also 
benefit the study, especially considering one of the outcomes (in-hospital mortality) that could not be 
correctly evaluated because of lack of cases. 
In conclusion, this study shows evidence that the NLR at admission of patients presenting with AP should 
be considered as an effective, easy and rapid tool of assessing AP severity and adverse outcomes (namely, 
development of organ failure, need for ICU admission and longer hospitalizations). A cut-off point of 9,2 
seems to be the most accurate at predicting all the referred outcomes in this sample. 
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 Table 1. Sample descriptive statistics (n = 445) 
   All MAP SAP 
  n 445 391 54 
      
Demographics  Age (years) 62,3 ± 18,4 61,1 ± 18,1 70,9 ± 18,4  
  Gender, male (%) 250 (56,2%)  222 (56,8%) 28 (51,9%) 
      
Etiology, n (%)  Biliary 279 (62,7%) 245 (62,7%) 34 (63,0%) 
  Alcoholic 73 (16,4%) 66 (16,9%) 7 (13,0%) 
  Idiopathic 72 (16,2%) 60 (15,3%) 12 (22,2%) 
  Others 21 (4,6%) 20 (5,1%) 1 (1,9%) 
      
Laboratory data  
(at admission) 
 
 
Hemoglobin (g/dL) 13,7 ± 1,9 13,9 ± 1,8 12,2 ± 2,4 
  White Blood Cells (x10
9
/L) 12,5 ± 5,4 12,5 ± 5,3 12,8 ± 6,2 
  Neutrophils (x10
9
/L) 10,2 ± 5,6 10,1 ± 5,6 10,6 ± 5,6 
  Lymphocytes (x10
9
/L) 1,6 ± 2,2 1,7 ± 2,3 1,1 ± 0,9 
  Glucose (mg/dL) 142,7 ± 60,7 140,0 ± 54,1 163,3 ± 95,8 
  C-Reactive Protein (mg/dL) 48,4 ± 69,9 42,7 ± 65,8 88,6 ± 84,1 
  Total bilirrubin (mg/dL) 2,0 ± 2,1 2,0 ± 2,1 2,2 ± 2,4 
  Direct bilirrubin (mg/dL) 1,1 ± 1,6 1,0 ± 1,6 1,2 ± 1,6 
  Urea (mg/dL) 41,7 ± 26,0 37,3 ± 16,4 74,1 ± 50,1 
  Creatinin (mg/dL) 1,0 ± 0,83 0,8 ± 0,3 2,2 ± 1,9 
  LDH (U/L)  381,2 ± 427,6 374,0 ± 391,2 423,4 ± 603,8 
  AST (U/L) 250,7 ± 497,4 249,6 ± 433,0 258,5 ± 823,8 
      
Clinical data  Abdominal pain, n (%) 428 (96,2%)  377 (96,4%) 51 (94,4%) 
   Death, n (%) 18 (4,0%)  6 (1,5%) 12 (22,2%) 
   ICU admission, n (%) 51 (11,5%) 29 (7,4%)  22 (40,7%) 
   LOS (days) 9,0 ± 12,9 8,0 ± 11,1 15,8 ± 20,6 
  LOS > 7 days, n (%) 171 (38,5%) 139 (35,6%) 32 (59,3%) 
   Organ Failure, n (%) 46 (10,3%)  0 (0%)  46 (85,1%) 
  NLR 10,1 ± 9,4 10,1 ± 9,4 13,9 ± 13,6 
Data is presented as mean ± standard deviation, unless noted otherwise. 
MAP = mild acute pancreatitis, SAP = severe acute pancreatitis, LDH = Lactate dehydrogenase, AST = Aspartate transaminase, 
ICU = intensive care unit, LOS = length of stay, NLR = neutrophil-lymphocyte ratio. 
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Table 2. AUC of ROC curves for each studied outcome and their respective cut-off value with better 
performance (higher sensitivity and specificity). 
 
Outcome 
 
AUC (95% CI) 
Optimal NLR 
cut-off 
Severity 
 
0,623 (0,549-0,698) 9,21 
Organ failure 
 
0,614 (0,530-0,698) 9,20 
LOS > 7 days 
 
0,605 (0,551-0,659) 7,89 
ICU admission 
 
0,684 (0,600-0,768) 9,17 
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Table 3. Sensitivity, specificity, PPV and NPV of cut-off point NLR = 9,2 at predicting AP severity, 
occurrence of organ failure, need for ICU admission and length of stay > 7 days.  
 
 Sensitivity Specificity PPV NPV 
Severity  53,7% 65,5% 17,8% 91,1% 
Organ Failure  54,3% 65,3% 15,2% 92,5% 
ICU admission  68,6% 57,0% 20,7% 94,5% 
LOS > 7 days  47,6% 69,2% 50,6% 66,7% 
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Figure 1. NLR cases distribution by acute pancreatitis severity. Measures of position are as follows:  
MAP – 25th percentile = 4,0; Median/50th percentile = 7,0; 75th percentile = 12,9. 
SAP – 25th percentile = 6,1; Median/50th percentile = 9,3; 75th percentile = 16,8. 
 
  
 
MAP = mild acute pancreatitis; SAP = severe acute pancreatitis.  
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Figure 2. ROC curve for NLR at admission predicting AP severity. 
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